BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Friday, December 5, 2025
Home
»
Newsletters
» BioWorld Science
BioWorld Science
June 8, 2007
View Archived Issues
Novel therapeutic agents for thrombotic and other blood coagulation disorders reported in patents
Read More
Heat shock protein 70 gene therapy safe, effective in phase I cancer study
Read More
Favorable endometrial profile seen with bazedoxifene in postmenopausal women
Read More
Progress on gene therapies reported
Read More
THCV begins phase I for obesity and metabolic disorders
Read More
Eurand and GSK reach milestone in orally disintegrating tablet collaboration
Read More
Sunesis earns milestone on progress of novel LFA-1 inhibitor candidate
Read More
MAGE-A3 cancer immunotherapeutic begins phase III study in NSCLC
Read More
Novel analgesic agents imparted in recent patent literature
Read More
New treatment options for neurological disorders reported in recent patent literature
Read More
Phase III enrollment stopped for SECTA therapy on DMC advice
Read More
Further development of XTL-2125 suspended
Read More
Interim RECORD data support Avandia safety; FDA requests more prominent product labeling
Read More
M-0002 begins phase IIa study in ascites
Read More
SLx-4090 studied in new phase IIa for dyslipidemia
Read More
Modulation of purinergic P2X and P2X2/3 receptors, a new strategy for treating urinary incontinence
Read More
Indigo inlicenses drug for treatment of arteriosclerosis obliterans
Read More
Amgen to acquire Alantos
Read More
CYT-107 to begin phase I/IIa trials in hepatitis C and oncology
Read More
Oral laquinimod to begin phase III program in relapsing MS
Read More
PF-562271 associated with activity and manageable toxicity in ongoing phase I trial
Read More
Tapestry's third-generation taxane TPI-287 advances through the pipeline
Read More
Targeted chemotherapeutic EC-145 advances to phase II clinical trials
Read More
Ongoing phase I clinical trials evaluating different dose schedules of E-7974
Read More
Antisense p53 production inhibitor improves efficacy and tolerability of cytarabine/idarubicin
Read More
Actemra significantly improves signs and symptoms of rheumatoid arthritis
Read More
AN-2728 shows comparable efficacy to betamethasone and tacrolimus in psoriasis
Read More
Japanese priority review for Taxotere in hormone refractory prostate cancer
Read More
E.U. approval for Humira for severe Crohn's disease
Read More
Remicade approved in E.U. for pediatric Crohn's disease
Read More